Valuation Abbott Laboratories Bulgaria S.E.
Stocks
ABL
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Tradegate
20:13:22 01/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 94.71 EUR | +27.85% |
|
0.00% | -30.19% |
| 05:13pm | Medtronic Raises Full-Year Outlook Following Fiscal First-Quarter Beat | MT |
| 03:53pm | Oncology firm Novocure says cyberattack exposed US patient records | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 190,965 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -12.34% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 214,904 | 211,922 | 208,232 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -3.31% | -1.39% | -1.74% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 31.7x | 24.4x | 21.8x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.99x | 3.82x | 3.62x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.04x | 0.8x | 1.8x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.8x | 3.49x | 3.27x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.27x | 3.88x | 3.57x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 16.4x | 14.5x | 13x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 18.3x | 16.3x | 14.5x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 27.1x | 22.6x | 20.4x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.69% | 4.42% | 4.9% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.33% | 2.48% | 2.62% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.486 | 4.524 | 5.074 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.7% | 60.6% | 57.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,302 | 54,646 | 58,409 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,090 | 14,598 | 16,020 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,313 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,232 | 7,924 | 8,850 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 110.36 | 110.36 | 110.36 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.66x | 4.27x | 16.42x | 2.33% | 191B | |
| 20.41x | 3.54x | 12.48x | 3.28% | 116B | |
| 17.72x | 0.21x | 12.93x | 0.74% | 61.75B | |
| 36.25x | 3.48x | 11.93x | 2.09% | 51.24B | |
| 30.15x | 7.44x | 19.2x | 1.32% | 51.51B | |
| 36.5x | 6.42x | 20.17x | -.--% | 34.36B | |
| 45.98x | 1.3x | 12.01x | 0.17% | 30.73B | |
| 39.78x | 6.96x | 24.99x | 0.26% | 24.01B | |
| 19.43x | 3x | 10.94x | 1.48% | 23.23B | |
| Average | 30.88x | 4.07x | 15.68x | 1.3% | 64.87B | |
| Weighted average by Cap. | 29.11x | 3.94x | 15.24x | 1.87% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABL Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
